Recent report showed that ER signal is one of the HER2-resistance signal pathways, and blocking both ER and HER2 signal with fulvestrant and neratinib could be a good way to overcome HER2 resisatance.16 In this study, ~50% of patients had ER + /HER2 + breast cancer. Here, ERBB2 is linked to breast carcinoma.